Published in Clin Cancer Res on May 15, 2005
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | NCT00868192
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer (2009) 1.53
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol (2014) 1.18
Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies. J Cancer Res Clin Oncol (2013) 1.08
Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis (2010) 1.07
Antiangiogenic drugs in ovarian cancer. Br J Cancer (2008) 1.06
Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies. J Gynecol Oncol (2010) 0.94
Expression of tumor suppressor gene ING4 in ovarian carcinoma is correlated with microvessel density. J Cancer Res Clin Oncol (2012) 0.87
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers (Basel) (2010) 0.83
Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma. PLoS One (2008) 0.82
Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer. Mol Cancer Ther (2012) 0.79
Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application. J Oncol (2011) 0.79
The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I-II. Int J Oncol (2016) 0.78
Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines. Front Oncol (2014) 0.77
Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo. Oncol Lett (2012) 0.77
Targeted therapies in epithelial ovarian cancer. Cancers (Basel) (2010) 0.77
Expression of ING4 is negatively correlated with cellular proliferation and microvessel density in human glioma. Oncol Lett (2017) 0.75
Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst (2004) 3.43
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87
Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer (2004) 2.59
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res (2003) 2.50
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer (2003) 2.48
Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents. Pediatr Infect Dis J (2007) 1.88
Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst (2002) 1.87
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol (2005) 1.84
Human papillomavirus prevalence and types in newborns and parents: concordance and modes of transmission. Sex Transm Dis (2004) 1.80
Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res (2004) 1.58
Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res (2002) 1.57
Competency assessment of residents in surgical pathology using virtual microscopy. Hum Pathol (2009) 1.54
Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res (2009) 1.53
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res (2011) 1.52
Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res (2006) 1.51
In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol (2005) 1.49
Coauthorship in pathology, a comparison with physics and a survery-generated and member-preferred authorship guideline. MedGenMed (2004) 1.45
Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer (2002) 1.45
Suppression of the malignant phenotype in human pancreatic cancer cells by the overexpression of manganese superoxide dismutase. Mol Cancer Ther (2003) 1.45
p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma. Cancer Biol Ther (2002) 1.41
Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging (2003) 1.40
Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer (2007) 1.39
Presentation, prognostic factors and patterns of failure in adult rhabdomyosarcoma. Sarcoma (2003) 1.32
Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst (2002) 1.31
Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells. Oncogene (2005) 1.30
Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther (2006) 1.30
Quality of life and mood in women with gynecologic cancer: a one year prospective study. Cancer (2002) 1.28
Inhibition of cell growth by overexpression of manganese superoxide dismutase (MnSOD) in human pancreatic carcinoma. Free Radic Res (2004) 1.25
DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics (2008) 1.17
Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol (2002) 1.17
Overexpression of manganese or copper-zinc superoxide dismutase inhibits breast cancer growth. Free Radic Biol Med (2006) 1.16
Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol (2002) 1.15
Alcohol dehydrogenase 3 and risk of squamous cell carcinomas of the head and neck. Cancer Epidemiol Biomarkers Prev (2005) 1.13
Gonorrhea and chlamydia infection among women visiting family planning clinics: racial variation in prevalence and predictors. Perspect Sex Reprod Health (2005) 1.11
Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis (2010) 1.07
Cancer attributions, distress, and health practices among gynecologic cancer survivors. Psychosom Med (2005) 1.03
Redox regulation of pancreatic cancer cell growth: role of glutathione peroxidase in the suppression of the malignant phenotype. Hum Gene Ther (2004) 1.01
Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1. Cancer Biol Ther (2005) 1.01
The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement. Immunogenetics (2006) 1.00
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol (2004) 0.98
Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol (2008) 0.98
Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res (2002) 0.97
Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines. Gynecol Oncol (2011) 0.97
Preoperative hypoalbuminemia is an independent predictor of poor perioperative outcomes in women undergoing open surgery for gynecologic malignancies. Gynecol Oncol (2013) 0.96
Does pretreatment seropositivity to human papillomavirus have prognostic significance for head and neck cancers? Cancer Epidemiol Biomarkers Prev (2008) 0.96
Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecol Oncol (2012) 0.95
Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecol Oncol (2005) 0.95
Metastatic progression of pancreatic cancer: changes in antioxidant enzymes and cell growth. Clin Exp Metastasis (2006) 0.95
Overexpression of manganese superoxide dismutase promotes the survival of prostate cancer cells exposed to hyperthermia. Free Radic Res (2004) 0.95
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol (2009) 0.93
Inhibition of oral cancer cell growth by adenovirusMnSOD plus BCNU treatment. Free Radic Biol Med (2003) 0.93
Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer (2007) 0.92
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol (2010) 0.92
Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis. Matrix Biol (2012) 0.92
Treatment of pancreatic cancer cells with dicumarol induces cytotoxicity and oxidative stress. Clin Cancer Res (2004) 0.91
p21 expression predicts outcome in p53-null ovarian carcinoma. Clin Cancer Res (2003) 0.90
The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. Surg Neurol (2008) 0.90
Head and neck cancer associated with herpes simplex virus 1 and 2 and other risk factors. Oral Oncol (2006) 0.89
Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration. Gynecol Oncol (2005) 0.89
Targeted therapy in ovarian cancer. J Oncol (2010) 0.89
Prevalence and persistence of human papillomavirus in postmenopausal age women. Cancer Detect Prev (2003) 0.88
Cytokeratin 5/6 immunostaining in cutaneous adnexal neoplasms and metastatic adenocarcinoma. Am J Dermatopathol (2004) 0.88
Physician specialty is significantly associated with hormone replacement therapy use. Obstet Gynecol (2003) 0.88
C-erb B2 (Her2/neu) is neither overexpressed nor amplified in hepatic neoplasms. Appl Immunohistochem Mol Morphol (2002) 0.86
Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine. Anticancer Drugs (2003) 0.86
Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay. Cytometry A (2003) 0.85
Immunohistochemical analysis of biliary tract lesions. Appl Immunohistochem Mol Morphol (2004) 0.84
The impact of p53 protein core domain structural alteration on ovarian cancer survival. Clin Cancer Res (2003) 0.83
Recommendations for the reporting of surgically resected thymic epithelial tumors. Hum Pathol (2009) 0.83
Early microrecanalization of vas deferens following biodegradable graft implantation in bilaterally vasectomized rats. Asian J Androl (2009) 0.83
Ovarian cancer p53 mutation is associated with tumor microvessel density. Gynecol Oncol (2002) 0.83
The use of touch preparation for the evaluation of sentinel lymph nodes in breast cancer. Am J Surg (2009) 0.83
Interobserver reliability in the histopathological diagnosis of cartilaginous tumors in patients with multiple osteochondromas. Mod Pathol (2012) 0.82
Redox-related antimelanoma activity of ATN-224. Melanoma Res (2009) 0.82
Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol (2003) 0.82
The role of appendectomy for mucinous ovarian neoplasms. Am J Obstet Gynecol (2012) 0.82
Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemother Pharmacol (2011) 0.82
Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study. Gynecol Oncol (2010) 0.82
Case-control study of vulvar vestibulitis risk associated with genital infections. Infect Dis Obstet Gynecol (2002) 0.82
A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. J Neurooncol (2004) 0.82
Local control of parameningeal rhabdomyosarcoma: outcomes in non-complete responders to chemoradiation. Med Pediatr Oncol (2003) 0.81
Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. Leuk Lymphoma (2006) 0.81
The influence of microvessel density on ovarian carcinogenesis. Gynecol Oncol (2003) 0.81
A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder. Cancer Chemother Pharmacol (2013) 0.81
Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors. Cancer (2003) 0.81
Gene expression profiling of in vitro radiation resistance in cervical carcinoma: a feasibility study. Gynecol Oncol (2005) 0.80
Development of an in vitro chemo-radiation response assay for cervical carcinoma. Gynecol Oncol (2002) 0.80
A preliminary diagnosis service provides prospective blinded dual-review of all general surgical pathology cases in an academic practice. Am J Surg Pathol (2005) 0.79
Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma. Am J Obstet Gynecol (2003) 0.79
Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens. Breast Cancer Res Treat (2002) 0.79
Pharmacogenomics of colorectal cancer prevention and treatment. Cancer Invest (2006) 0.78
Recommendations for the reporting of surgically resected thymic epithelial tumors. Am J Clin Pathol (2009) 0.77
Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens. J Neurooncol (2002) 0.76
Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin Cancer Res (2004) 0.76
Measurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring. Technol Cancer Res Treat (2002) 0.75